NuPathe, a specialty pharma seeking approval for Zelrix, a patch for migraine treatment, will see its quiet period end on Tuesday, September 14. On August 5, the company raised $50 million by offering 5 million shares at $10, below the range of $14-$16. ...read more
NuPathe, a specialty pharmaceutical company that has developed a patch for migraine treatment, raised $50 million by offering 5 million shares at $10, well below the proposed $14 to $16 range. The company's venture backers, Quaker BioVentures, Safeguard...read more
NuPathe, a specialty pharmaceutical company that has developed a patch for migraine treatment, significantly reduced the proposed price for its upcoming IPO from a range of $14-$16 to $10 per share. The company now expects to raise $50 million in gross...read more
NuPathe, which is developing Zelrix, a migraine treatment that completed Phase 3 trials and expects to launch in 2012, announced terms for its IPO on Wednesday. The Conshohocken, PA-based company plans to raise $75 million by offering 5 million shares at a...read more
NuPathe quiet period ends September 14
NuPathe, a specialty pharma seeking approval for Zelrix, a patch for migraine treatment, will see its quiet period end on Tuesday, September 14. On August 5, the company raised $50 million by offering 5 million shares at $10, below the range of $14-$16. ...read more
NuPathe prices IPO at $10, below the range
NuPathe, a specialty pharmaceutical company that has developed a patch for migraine treatment, raised $50 million by offering 5 million shares at $10, well below the proposed $14 to $16 range. The company's venture backers, Quaker BioVentures, Safeguard...read more
NuPathe significantly reduces proposed IPO deal size
NuPathe, a specialty pharmaceutical company that has developed a patch for migraine treatment, significantly reduced the proposed price for its upcoming IPO from a range of $14-$16 to $10 per share. The company now expects to raise $50 million in gross...read more
Pharmaceutical company NuPathe sets IPO terms and timing
NuPathe, which is developing Zelrix, a migraine treatment that completed Phase 3 trials and expects to launch in 2012, announced terms for its IPO on Wednesday. The Conshohocken, PA-based company plans to raise $75 million by offering 5 million shares at a...read more